Paroxetine — Non-Hormonal Vasomotor Symptom Support

Route: Oral (capsule or tablet).

• Administer once daily, typically at bedtime to minimize daytime sedation and align with the circadian pattern of vasomotor symptoms.
• May be taken with or without food; consistency with food intake is recommended.
• Swallow whole with water. Do not crush or chew extended-release formulations.
• A therapeutic effect on vasomotor symptoms may be apparent within 1–2 weeks of initiation; full benefit is typically seen at 4–6 weeks.

Prescriber-directed dosing. Established evidence supports:

• Paroxetine mesylate (Brisdelle): 7.5 mg once daily at bedtime—the only FDA-approved dose for vasomotor symptoms.
• Paroxetine HCl (off-label for VMS): 10–25 mg/day; 10 mg is typically better tolerated with comparable efficacy to 20 mg for VMS.
• Do not discontinue abruptly—taper under prescriber supervision to avoid discontinuation syndrome.
• All dosing is determined by the prescribing clinician based on the patient's symptom burden, comorbidities, and medication history.

• Paroxetine: Potently and selectively inhibits the serotonin reuptake transporter (SERT), increasing synaptic serotonin concentrations in the central nervous system. In the context of vasomotor symptoms, the proposed mechanism involves serotonin-mediated modulation of the hypothalamic thermoregulatory zone: declining estrogen levels narrow the thermoregulatory set-point in the hypothalamus, increasing sensitivity to minor temperature fluctuations. Enhanced serotonergic tone is hypothesized to recalibrate this threshold. Additionally, increased serotonin promotes central vasodilation, opposing the peripheral vasodilation that manifests as flushing. The exact mechanism of paroxetine's anti-vasomotor effect has not been definitively established.

Indication context: Compounded paroxetine may be prescribed as a non-hormonal alternative for perimenopausal and postmenopausal women experiencing bothersome vasomotor symptoms who have contraindications to, or preference against, estrogen-based therapies. Candidate populations include women with estrogen-receptor-positive breast cancer history, elevated thromboembolic risk, or personal preference for a non-hormonal option.

Important clinical note on tamoxifen: Paroxetine is a potent CYP2D6 inhibitor. In women taking tamoxifen for breast cancer, CYP2D6 inhibition reduces conversion of tamoxifen to its active metabolite endoxifen, potentially compromising efficacy. Paroxetine should generally be avoided in patients on tamoxifen; alternative SSRIs with lower CYP2D6 inhibitory potential (e.g., venlafaxine, escitalopram) are preferred.

Monitoring:

• Assess vasomotor symptom frequency and severity at 4–6 weeks.
• Monitor for mood changes, suicidal ideation (especially during initiation), hyponatremia, and sexual dysfunction.
• Annual review of continued need and dose; encourage non-pharmacological strategies concurrently.

Contraindications:

• Concurrent or recent (within 14 days) use of monoamine oxidase inhibitors (MAOIs)—risk of serotonin syndrome.
• Concurrent use of thioridazine or pimozide (risk of QTc prolongation and serious cardiac arrhythmia).
• Hypersensitivity to paroxetine or any formulation component.

Warnings & Precautions:

• Black box warning: Increased risk of suicidal thinking and behavior in children, adolescents, and young adults (though VMS indication is in adult women, the label applies).
• Serotonin syndrome: risk increased with concurrent serotonergic agents (triptans, tramadol, linezolid, lithium, other SSRIs/SNRIs); observe for agitation, hyperthermia, clonus, tremor.
• Discontinuation syndrome: Do not stop abruptly—taper gradually; symptoms include dizziness, paresthesias, nausea, anxiety, vivid dreams.
• Hyponatremia (SIADH): monitor electrolytes in elderly or at-risk patients.
• Bleeding risk: NSAIDs, anticoagulants, or antiplatelet agents combined with SSRIs increase GI or other bleeding risk.
• QTc prolongation has been reported at higher doses; use with caution with other QT-prolonging agents.

Drug Interactions:

• MAOIs: absolute contraindication.
• Tamoxifen: avoid; paroxetine inhibits CYP2D6 and reduces endoxifen formation.
• Strong CYP2D6 inhibitors/substrates: paroxetine is itself a strong CYP2D6 inhibitor—adjust doses of CYP2D6-metabolized co-medications.
• Warfarin: enhanced anticoagulant effect; monitor INR.

Common Side Effects: Headache, fatigue, nausea/vomiting (most common in early weeks), somnolence; sexual dysfunction less common at low VMS doses than at higher psychiatric doses.

Store at room temperature (15–30°C / 59–86°F). Protect from moisture, heat, and direct light. Keep tightly capped in the dispensing container. Use within the beyond-use date assigned by Genesis Compounding. Keep out of reach of children.

Why would a prescriber choose paroxetine for hot flashes instead of hormones?

Some women cannot use estrogen (e.g., due to a history of hormone receptor-positive breast cancer, thromboembolic disease, or certain cardiovascular conditions) or prefer a non-hormonal option. Paroxetine is the only FDA-approved non-hormonal prescription therapy specifically for moderate-to-severe vasomotor symptoms.

How long before I notice improvement in hot flashes?

Some improvement in vasomotor symptom frequency and severity may be noticeable within 1–2 weeks, with full benefit typically seen after 4–6 weeks of consistent daily use.

Can I take paroxetine with my other medications?

Paroxetine interacts with multiple drug classes. Most critically, it must not be combined with MAOIs, and women taking tamoxifen for breast cancer should generally avoid paroxetine. Provide your prescriber and pharmacist with a complete medication list before starting.

What happens if I stop taking paroxetine suddenly?

Abrupt discontinuation of paroxetine can cause a discontinuation syndrome including dizziness, nausea, electric shock-like sensations (“brain zaps”), anxiety, and irritability. Always taper the dose gradually under prescriber guidance when discontinuing.

Is this product FDA-approved?

Paroxetine mesylate 7.5 mg (brand name Brisdelle) is FDA-approved for moderate-to-severe vasomotor symptoms. This compounded preparation is prepared by Genesis Compounding as a patient-specific 503A product and is not itself FDA-approved as a compounded drug.